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Background: Epilepsy appears in 70e80% of patients with tuberous sclerosis complex, most
commonly in the first year of age. Early manifestation of epilepsy is associated with drug-
resistant epilepsy and mental retardation in more than 80% of patients. Clinical epileptic
seizures are preceded by deterioration of EEG recording thus infants with high risk of
epilepsy can be identified.
Aims:We hypothesized that preventative antiepileptic treatment of infants with multifocal
activity on EEG might lower the incidence of drug-resistant epilepsy and mental
retardation.
Methods: Forty-five infants with early diagnosis of tuberous sclerosis complex were
included in the open-label study. They were divided in two groups: standard (n¼ 31) and
preventative one (n¼ 14). In standard group the antiepileptic treatment was launched
early, but after the onset of seizures. In preventative group medication was commenced
when active epileptic discharges were seen on EEG, but before the onset of clinical seizures.
Children were followed till the end of 2 years of age.
Results: At 24 months of age mental retardation was significantly more frequent and severe
in “standard” vs “preventative” group (48% vs 14%; p¼ 0.031; mean IQ score 68.7 vs 92.3;
p< 0.05). The “preventative” group was characterized by higher ratio of seizure-free
patients (93% vs 35%; p¼ 0.004), lower incidence of drug-resistant epilepsy (7% vs 42%;
p¼ 0.021) and lower number of patients requiring polytherapy (21% vs 55%; 0.039) than the
“standard group.; fax: þ48 22 8157402.
om (S. Jo´zwiak).
ean Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
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and high risk of epilepsy markedly improves their neurodevelopmental outcome and
reduces the incidence of drug-resistant seizures.
ª 2011 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights
reserved.1. Introduction Epileptology, The Children’s Memorial Health Institute, War-Tuberous sclerosis complex (TSC) is amultisystem, autosomal
dominant disorder with an incidence of approximately 1 in
6000 livebirths,1 that manifests itself with hamartomatous
growths most commonly affecting the brain, skin, kidneys,
heart, liver, eyes and lungs.2 Molecular genetic studies have
revealed two genes responsible for the development of clinical
phenotypes: TSC1 on 9q34 and TSC2 on 16p13.2
Neurological manifestations, including seizures and
mental retardation, are major morbidity causes in patients
with tuberous sclerosis complex.3 Epilepsy is the most
common symptom appearing in 80 to 90% of patients, mainly
in the first year of life.3,4
The prevalence of mental retardation is 40e70%5e7 and
severe or profound mental retardation (defined as IQ lower
than 36) is reported in 30e45% of patients.8,9 There is a strong
association between mental retardation and epilepsy. In the
large series of 160 patients from Mayo Clinic Gomez found
that all patients with mental retardation had history of
epilepsy, and none without seizures had mental retardation.3
These findings were confirmed by recent studies.7,10 Early
onset of epilepsy in tuberous sclerosis complex, especially
manifested by infantile spasms, is critically associated with
severe forms of mental retardation.5,6,7,10
The earliest symptoms of TSC include heart tumors and
cortical tubers, which can be seen even prenatally.2 Intro-
duction of routine fetal echocardiography and increasing
availability of fetal MRI in recent years gave us a possibility to
diagnose tuberous sclerosis complex very early and follow up
these children prospectively.
Wepresent the first unbiased, prospective study of a group of
children diagnosed with tuberous sclerosis complex prenatally
or perinatally and regularly seen from the first months of life.
Analysis of their EEG evolution and epilepsy characteristics
enabled us to identify the children with high risk of epilepsy
and mental retardation. In this group of patients we introduced
a novel approach to epilepsy management. Preventative anti-
epileptic treatmentwasgivento infantswithepilepticdischarges
on EEG before the onset of clinical seizures. We present results
of first comparative study of “standard” and “preventative”
approaches and their impact on neurodevelopmental outcome
of children with tuberous sclerosis complex.2. Material and methods
2.1. Subjects
The study population for this prospective trial consisted of
infants admitted to the Department of Neurology andsaw, Poland, with diagnosis of tuberous sclerosis complex
established until the end of the secondmonth of life according
to criteria of Roach et al.11 Most infants had multiple cardiac
tumors revealed on prenatal echocardiography and subse-
quent neuroimaging and/or skin examination confirmed the
diagnosis of TSC. Children presenting with seizures as
a reason of referral were not enrolled in this study to avoid
ascertainment bias. All the patients were followed-up at least
till the end of 24 month of life.
2.2. Study design
We describe two groups of patients, according to the applied
method of antiepileptic treatment: (1) a group with “standard”
approach; medication with antiepileptic drugs was launched
within a week after the onset of seizures (group S), and (2)
a group with “preventative” treatment of epilepsy
commencedwithin aweek after appearance of active epileptic
discharges on consecutive EEG, but before clinical seizures
(group P). Both groups were followed prospectively till the end
of 24th month of age.
Infants recruited between 2000 and 2006 were managed
according to the standard epilepsy guidelines. The parents
were informed about the tuberous sclerosis complex diag-
nosis and high risk of seizures and trained in seizures recog-
nition. They were aware of contacting our study personnel as
soon as they saw the seizures in order to facilitate early
antiepileptic treatment.
The infants recruited between 2006 and 2008 were offered
a new approach. Starting from the point when tuberous
sclerosis complex diagnosis was established, electroenceph-
alography was performed every 6 weeks and antiepileptic
treatment was introduced as soon as epileptic discharges,
defined as multifocal spikes, appeared on EEG. Patients with
normal EEG recordings remained in follow up without anti-
epileptic medication.
In both groups of children, the antiepileptic drug of first
choice was vigabatrin. The dosage regimen was 100e150 mg/
kg per day. The visual field deficit is the well-recognized side
effect of vigabatrin, but it cannot be adequately measured in
infants and small children. In order to assess the impact of
vigabatrin on vision in our patients, all children in P group and
16 children in S group underwent Visual Evoked Potentials
(VEPs) examination before the introduction of vigabatrin and
every 6 months during treatment.
All infantswere seenevery 6weeks toassess the efficacyand
safety of treatment. Follow-up neuropsychological assessment
was performed in all infants at the age of 24months.
The open-label study protocol was approved by the insti-
tutional bioethics committee of The Children’s Memorial
Table 1 e Electroencephalography findings in both
groups of patients.
Standard
care group
(n¼ 31)
Preventative
group
(n¼ 14)
p-Value
Patients with
epileptiform
discharges on EEG
22 (71%) 10 (71.4%) Not
significant
Patients with 7/31 (22.6%) 1/14 (7.1%) p¼ 0.405
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consent was obtained from the parents of the patients.
2.3. Outcome measures
The primary efficacy outcome for all study subjects was the
result of neuropsychological evaluation at the age of 24months.
Secondary efficacy outcomes included occurrence of
epilepsy, age at epilepsy onset, morphology of seizures,
number of seizure-free patients, drug resistance of epilepsy,
number of patients with EEG normalization. Seizure freedom
at the end of the study was defined as at least four-month
period with no seizures. Epilepsy was considered as drug
resistant if the patient continued to have two ormore seizures
permonthdespite the use of twoormore antiepileptic drugs.12
2.4. EEGs evaluation
The EEG reports were assessed for the presence of disorgani-
zation of background activity, and focal, multifocal or gener-
alized epileptic discharges. EEG was analyzed by an
epileptologistwhowasblinded to themanagement ofpatients.
2.5. Neuropsychological assessment
All patients underwent neuropsychological evaluation based
on Psyche-Cattell test at the age of 24 months by certified
neuropsychologist blinded to the management of the patient.
Patients were classified as intellectually normal when their
score was 69 or more. Those with an IQ <69 were considered
mentally retarded. Children with scores between 52 and 68
were classified as having mild mental retardation, those with
score between 36 and 51 were classified as moderately
retarded, and those with score 35 or less received a diagnosis
of severe or profound mental retardation.
2.6. Statistical analysis
The statistical significant differences of the frequencies
between the groups were assessed using the chi-square test
for 2 2 tables. Depending on the number of observations in
the table either regular Chi-square test was used, its corrected
version, or the one with Yates correction.
The distribution of the quantitative variables was checked
using ShapiroeWilks and KolmogoroveSmirnov tests. In case
of non-normally distributed variables they were summarized
by range and median. The differences between the groups
were checked using KolmogoroveSmirnov test.
Two-tailored p-value less than 0.05 was considered to
indicate statistical significance.
hypsarrhythmia 7/22 with
epilepsy
1/10 with
epileptic EEG
p¼ 0.378
Normal EEG at the age
of 24 months
11/31 12/14 p¼ 0.005*
Patients whose EEG turned to normal
Whole group 2/31 8/14 p¼ 0.0007*
Pts receiving AEDs 2/22 8/10 p¼ 0.0001*
AED, antiepileptic drug.
*Statistically significant values.3. Results
3.1. Demographic data
Thirty one patients (17 girls and 14 boys) were enrolled to S
group and 14 patients (8 girls and 6 boys) were enrolled to P
group. In all patients, 24-month-long follow-up wascompleted. Twenty-five patients in S group and 7 in P group
underwent mutational analysis.
Therewere 6patientswithTSC1mutationand17withTSC2
mutation in S group. In 2 cases in this group no mutation was
identified. There was a similar proportion of TSC1/TSC2
mutations found in P group,with 2 and5patients, respectively.3.2. EEG evaluation
3.2.1. Standard treatment group
In S group, EEGwas routinely performed after seizure onset. In
6 patients, however, EEG was recorded before the onset of
seizures demonstrating normal pattern in all recordings.
EEG recorded after the onset of seizures in S group showed
hypsarrhythmia in 7 cases (23% of all patients in this group;
32% of patients with epilepsy), generalized multiple spikes or
spike-wave activity in 8 cases (26%; or 36%, respectively), or
localized spikes in 7 patients (23%; or 32%, respectively).
Despite antiepileptic treatment, only in 2 patients (6% or 9% of
patients with epilepsy) EEG turned to normal in the first two
years of life.
3.2.2. Preventative group
In P group, EEGwas performed every 6weeks starting from the
enrollment visit, till the end of 24-month follow-up. In 4
patients (29%), EEG remained normal throughout the study. In
10 patients initial EEG was normal and then deterioration was
shown. Median age at epileptiform discharges onset in this
group was 4 months. In 8 (57%) cases localized spikes and
spike-wave activitywas recorded, in 1 (7%) patient generalized
polyspike activity, and in 1 (7%) patient hypsarrhythmia was
recognized. In these patients, preventative antiepileptic
treatment with vigabatrin was introduced. Preventative
approach was associated with significantly higher number of
patients whose EEG turned out to be normal at the age of 2
years ( p¼ 0.0007 comparing whole S and P groups; or
p¼ 0.0001 comparing only treated patients within P and S
group) (Tables 1e3).
Table 2 e Clinical findings and characteristics in patients with standard approach (S group).
Cases: No/
gender/age at
diagnosis
TSC criteria
fulfilled at
enrollment
Seizure
onset
(months)
Time from
seizure to
treatment
onset
(days)
Seizure
type
Antiepileptic
drugs
Seizure
outcome
EEG
outcome
Neuropsychological
evaluation at 24
months of age
1, M, 1/12 MCT, SEN,
SEGA, CT
2.5 5 ISþ PMS VGB, VPA,
LEV, TPM, VNS
PMS
remain,
IS e
ceased
Multifocal discharges 48
2, F, 1/12 SEN, CT, HM 4 7 IS, PMS VGB, VPA PMS
remain,
IS e
ceased
Localized discharges 90
3, M, prenatal MCT, HM,
SEN,
CT, SEGA
5 2 IS, PMS VGB, VPA,
ACTH, TPM
IS, PMS HS 36
(severe hypoacusis)
4, F, 2/12 MCT, HM, CT,
SEN, SEGA
5 1 IS, PMS VGB, VPA,
TPM, ACTH
PMS
remain,
IS -
ceased
Multifocal discharges 41
5, F, prenatal MCT, HM,
SEN SEGA
8 7 PMS VGB, PMS Localized discharges 78
6, M, 2/12 HM, SEN, CT,
SEGA
5 5 PMS VGB, VPA PMS Multifocal discharges 55
7, F, 1/12 MCT, HM,
SEN,
No NA No No Seizure-
free
normal 99
8, M, 1/12 HM, SEN, CT,
SEGA
4 3 IS, PMS VGB, VPA,
ACTH
PMS
remain,
IS ceased
Multifocal discharges 37
9, F, 2/12 MCT, SEGA No NA No No Seizure-
free
Normal 111
10, F, prenatal MCT, SEN, CT 2 3 PMS VGB, VPA PMS Localized discharges 24
11, F, 1/12 MCT, CT 6 6 PMS VGB PMS Multifocal discharges 63
12, M, 1/12 MCT, HM, 3 3 IS, PMS VGB, VPA,
ACTH
PMS
remain,
IS ceased
Multifocal discharges 39
13, F, 2/12 MCT, HM, 5 5 IS, PMS VGB, VPA PMS
remain,
IS ceased
Multifocal discharges 55
14, M, 2/12 MCT, HM,
SEN, CT
2 7 IS, PMS VGB, VPA,
ACTH, TPM
IS, PMS HS, 38
15, F, 1/12 MCT, HM,
SEGA
4 5 PMS VGB, VPA,
ACTH
PMS Multifocal discharges 42
16, M, 2/12 MCT, HM, 10 5 PMS VGB, TPM PMS Localized discharges 70
17, M, prenatal MCT, HM,
SEN, CT
2,5 6 IS, PMS VGB, TPM IS, PMS Multifocal discharges 38
18, M, 1/12 MCT, HM,
SEGA, CT,
SEN
2 5 PMS VGB, VPA Seizure-
free
Multifocal discharges 61
19, F, 2/12 MCT, SEN No NA No No Seizure-
free
Normal 93
20, F, 1/12 MCT, SEN 5 7 IS VGB, VPA Seizure-
free
Normal 81
21, M, 2/12 MCT, HM 9 5 PMS VGB Seizure-
free
Multifocal discharges 74
22, F, 2/12 MCT, CT No NA No No Seizure-
free
Normal 89
23, M, 1/12 MCT, CT, SEN 15 7 PMS VGB PMS Multifocal discharges 67
24, F, 1/12 HM, CT, SEN No NA No No No Normal 97
25, F, 2/12 HM, CT No NA No No No Normal 94
26, M, 1/12 MCT, CT,
HM, SEN
No NA No No No Normal 91
27, F, 2/12 MCT, CT 10 5 PMS VGB Seizure-
free
Normal 97
(continued on next page)
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 5 ( 2 0 1 1 ) 4 2 4e4 3 1 427
Table 3 e Clinical findings and characteristics in patients with preventative approach (P group).
Cases: No/gender/
age at diagnosis
(months)
TSC criteria
fulfilled at
enrollment
Epileptic
discharges
onset
(months)
Seizure
onset
(months)
Seizure
type
Antiepileptic
drugs
Seizure
outcome
EEG
outcome
Neuropsychological
evaluation at 24
months of age
1, F. 1/12 MCT, HM, SEN,
SEGA, CT
3.5 5 ISþ PMS VGB, VPA,
LEV, TPM
PMS
remain, IS
e ceased
Normal 68
2, F. 1/12 SEN, CT 2.5 No No VGB Seizure-
free
Normal 101
3, F. 1/12 MCT, HM, SEN,
CT
3 6 PMS VGB, VPA,
ACTH, TPM
Seizure-
free
Localized
discharges
71
4, F. 1/12 MCT, HM, 2.5 No No VGB Seizure-
free
Normal 84
5, M. 1/12 MCT, HM, 5 5 PMS VGB, VPA Seizure-
free
Normal 110
6, M. 2/12 MCT, HM, SEN,
CT
4 No No VGB Seizure-
free
Normal 94
7, M. prenatal MCT, HM, SEN, 7 No No VGB Seizure-
free
Normal 98
8, F. 2/12 MCT, HM, SEN,
CT
4 4.5 PMS VGB Seizure-
free
Normal 58 (severe familial
hypoacusis)
9, M. prenatal MCT, HM, SEN,
CT
9 10 PMS VGB Seizure-
free
Normal 132
10.M 1/12 SEN, CT 15 17 PMS VGB, VPA Seizure-
free
Localized
discharges
88
11. M 1/12 MCT, SEN, CT No No No No Seizure-
free
Normal 97
12. F. 1/12 MCT, HM, SEN,
CT
No No No No Seizure-
free
Normal 96
13. F 1/12 MCT, HM, SEN,
CT
No No No No Seizure-
free
Normal 100
14. F 1/12 MCT, HM, SEN,
CT
No No No No Seizure-
free
Normal 95
M, male; F, female; MCT, prenatally found multiple cardiac tumors; HM, hypomelanotic macules (3 or more); CT, cortical tubers; SEN, sub-
ependymal nodules; SEGA, subependymal giant cell astrocytoma; IS, infantile seizure; PMS, partial motor seizures; VGB, vigabatrin; VPA, val-
proic acid; LEV, levetiracetam; TPM, topiramate; ACTH, adrenocorticotropic hormone.
Table 2 (continued )
Cases: No/
gender/age at
diagnosis
TSC criteria
fulfilled at
enrollment
Seizure
onset
(months)
Time from
seizure to
treatment
onset
(days)
Seizure
type
Antiepileptic
drugs
Seizure
outcome
EEG
outcome
Neuropsychological
evaluation at 24
months of age
28, F, 1/12 CT, SEN, HM No NA No No No Normal 106
29, M, 1/12 MCT, HM, CT 7 6 PMS VGB, TPM PMS Multifocal discharges 96
30, F, 1/12 MCT, HM,
SEGA
No NA No No No Normal 92
31, M, 1/12 MCT, SEGA,
SEN, CT
2 5 PMS, IS VGB, VPA,
TPM, CBZ
PMS HS 28
M, male; F, female; MCT, prenatally found multiple cardiac tumors; HM, hypomelanotic macules (3 or more); CT, cortical tubers; SEN, sub-
ependymal nodules; SEGA, subependymal giant cell astrocytoma; IS, infantile seizure; PMS, partial motor seizures; VGB, vigabatrin; VPA, val-
proic acid; LEV, levetiracetam; TPM, topiramate; NVS, nerve vagus stimulator; CBZ, carbamazepine; ACTH, adrenocorticotropic hormone; NA,
not applicable.
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Table 4 e Comparison of seizure severity and mental
outcome in standard and preventative treatment groups.
Standard
care group
(n¼ 31)
Preventative
group
(n¼ 14)
p-
Value
Number of patients with
epilepsy
22 (71.0%) 6 (42.9%) 0.072
Median age at epilepsy
onset (months)
5.0 5.5 0.138
Patients with infantile
spasms
11 (35.5%) 2 (14.3%) 0.151
Patients requiring epilepsy
polytherapy
17 (54.8%) 3 (21.4%) 0.039*
Patients with drug-resistant
epilepsy
13 (41.9%) 1 (7.1%) 0.021*
Seizure-free patients at the
age of 24 months
11 (35.4%)
2/22 with
epilepsy
13 (92.9%)
5/6 with
epilepsy
0.004*
0.0003*
Mean IQ score at the age of
24 months
68.7
Median 74.0
(Range
24e111)
92.3
Median 95.5
(Range
58e132)
p< 0.05*
Patients with intellectual
disability at the age of 24
15 (48.4%) 2 (14.3%) 0.031*
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 5 ( 2 0 1 1 ) 4 2 4e4 3 1 4293.3. Epilepsy outcomes
Seizures developed in 22 (71%) patients in S group and in 6
(43%) patients in P group ( p¼ 0.072) Mean time between the
onset of seizures and treatment initiation in S group was 5
days (ranging from 1 day to 7 days).
In P group, seizures developed only in patients with
previous EEG deterioration. All these patients had vigabatrin
started before the onset of seizures. In patients with normal
EEG,no seizureswere recorded.Medianageatonset of seizures
in S group was 5.0 months (range from 2 to 15months) and 5.5
months (range from 4 to 17 months) in P group ( p¼ 0.138).
In P group epilepsy was much better controlled. At the end
of the study, in P group only 1 of 6 patients with epilepsy (17%)
presented with active epilepsy, while in S group, 20 out of 22
children (91%) were still experiencing seizures ( p¼ 0.0003).
In P group, 3 patients required two or more antiepileptic
drugs to control seizures, while in S group, polytherapy was
necessary in 17 children ( p¼ 0.039).
Drug-resistant epilepsy was alsomore frequently observed
in S group: 13 patients (42%) in this group vs 1 child (7%) in P
group ( p¼ 0.021) (Table 4).
months
Patients with mild
intellectual disability at
the age of 24 months
5 (16.1%) 2 (14.3%) 0.876
Patients with moderate,
severe, and profound
intellectual disability at
the age of 24 months
10 (32.4%) 0 (0%) 0.036*
IQ, intellectual quotient.
*Statistically significant values.3.4. Neuropsychological assessment
Mental retardation was observed only in patients with
epilepsy. It was significantly more frequent in S than in P
group (15 patients, 48% vs 2 patients, 14%) ( p¼ 0.031). At the
age of 24 months, IQ score of patients in S group was signifi-
cantly lower than in P group: mean 68.7 (range from 24 to 111)
vs 92.3 (range from 58 to 132) ( p< 0.05). Median values were 74
and 95.5, correspondingly.
In S group, intellectual disabilitywas also significantlymore
severe than in P group. Severe and profound intellectual
disability was found in 2 (6%) patients and moderate in 8 (26%)
patients inSgroup.Nopatient inPgrouppresentedwith severe/
profound or moderate disability ( p¼ 0.043) (Fig. 1, Table 4).4. Discussion
This is the first study showing the beneficial effect of
preventative antiepileptic treatment on intellectual outcome
and epilepsy severity in children with high risk of epilepsy.
Our study population consisted of infants with tuberous
sclerosis complex and thus was homogenous in regard to
etiology of epilepsy. Mental retardation is common in
tuberous sclerosis complex and for parents receiving the
diagnosis in their child, it is themost overwhelming symptom
of the disease.
Several interrelated factors, including onset and type of
epilepsy, cortical tubers number and load, TSC1 or TSC2
mutation, and others, are believed to account for mental
retardation in this disorder.5,7 Our two groups of patients did
not differ in the initial tuberous sclerosis complex symptoms,
demographic data, and TSC1/TSC2 mutation ratio.
Themost striking fact is that vastmajority of patients, who
did not develop epilepsy, do not also develop mental retar-
dation.3,5,8,9 On the other hand, in epileptic patients,especially in those with history of infantile spasms, mental
retardation is recognized in 80e100%.5,13
In our study, we were successful to reduce the percentage
of patients with epilepsy by use of preventative antiepileptic
treatment. Consequently, only 14% of patients in this group
presented with intellectual disability and none had moderate
orworsemental retardation at the age of 24months. However,
as learned from other reports such treatment should be
maintained at least till the end of the second year of life.14
Several studies show12,15 that the longer the duration of
seizures from the onset to cessation, the greater the risk of
mental retardation. It is worth to note, that in our traditionally
treated patients, those with epilepsy received antiepileptic
drug in oneweekafter theonset of seizures as latest and still 15
out of 22 patients with epilepsy (68%) developedmental retar-
dation. Sixty-eight per cent, however, is less than previously
reported in series of patients in whom the treatment lag was
longer.3,5,13 This is in conjunction with the study of Bom-
bardieri et al.,15whofoundthat implementationofVGBasearly
as within a week from the onset of seizures resulted in better
cognitive outcome than delayed treatment. However, in their
group of patients, still 70% presented withmental retardation.
Recently, data is accumulating that the cognitive mani-
festations in epilepsy are associated with epileptic discharges
recorded on EEG.10,16e18 Prolonged duration of continuous
epileptic activity is considered to be deleterious for
Fig. 1 e Intellectual outcome in children of our cohort of 45 infants with early diagnosis of tuberous sclerosis complex,
depending on the approach to epilepsy management. (A) Antiepileptic treatment introduced within 1 week after clinical
seizures appearance; 52% of patients presented with normal IQ at the age of 24 months; (B) antiepileptic treatment was
introduced when epileptic activity appeared on EEG recording and before the onset of clinical seizures; 86% of patient
presented with normal IQ at the age of 24 months.
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 1 5 ( 2 0 1 1 ) 4 2 4e4 3 1430intellectual outcome in young children.16,18 Primec et al.19
showed that three weeks of hypsarrhytmia significantly
increases the risk of mental retardation in infants with
epilepsy. It was shown by Philippi et al.20 in their retrospective
study that hypsarrhytmia is preceded by gradual deterioration
of EEG over a period of 3e6 weeks. They called this clearly
distinguishable prehypsarrhytmic EEG pattern a “point of no
return”, as if not treated, all the children who reached it, later
developed West syndrome with mental retardation. The
authors introduced antiepileptic treatment in 4 children in
this prehypsarrhytmic period, despite no clinical seizures
being observed, and none of them developedWest syndrome.In our study, preventative antiepileptic treatment markedly
reduced the risk of mental retardation.
Philippi et al.20 showed also that hypsarrhytmia preceded
the onset of infantile spasms for up to 26 days. This means
that even if antiepileptic treatment was introduced at the day
of seizure onset, the childmight be as far as 3e10weeks ahead
of “point of no return” for mental deterioration. Our findings
indirectly provide further support for these statements, as the
median age of epilepsy onset was 5.5months, andmedian age
at the onset of epileptiform discharges on EEG was 4 months.
Moreover, damage to the brain made by constant epileptic
activity not only results in neuronal loss and disturbed
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expression of multidrug resistance gene thus leading to the
development of drug-resistant epilepsy.21 As shown in our
study, preventative antiepileptic treatment lowers risk of
drug-resistant epilepsy which confirm the results of similar
studies on preventative treatment from animal models.22
Cortical tubers in tuberous sclerosis complex show
reduced inhibition by gamma-aminobutyric acid (GABA)23 and
vigabatrin, an analogue of GABA, has been shown to be
particularly effective in treating infantile spasms owing to this
etiology.24,25 This drug was proposed as the first-line medi-
cation for infantile spasms as well as partial seizures in
tuberous sclerosis complex.15,24 Vigabatrin is considered to be
relatively safe in children, with the exemption of a specific
side effect of peripheral visual field defect occurring in about
15% of treated patients.26 However, Guzzetta et al.27 found no
visual impairment in infants with West syndrome, treated
with VGB. As the percentage of patients receiving antiepileptic
drugs in our two groups of patients did not differ, we believe
that we offered the preventative antiepileptic treatment only
to those children who without treatment would develop
epilepsy on further follow up.
In conclusion, our study shows that in children below 2
years of age treatment with vigabatrinmaymarkedly improve
the neuropsychological outcome in tuberous sclerosis
complex if commenced after the deterioration of EEG, but
before the onset of seizures.
At present we recommend to carry out neuroimaging and
skin examination in every child suspected of having tuberous
sclerosis complex, especially in newborns with multiple
cardiac tumors. If the diagnosis is confirmed, serial EEG
recordings should be performed to identify infants with high
risk of epilepsy. In those infants, antiepileptic treatment with
vigabatrin should be introduced and continued till the end of
the second year of age.Acknowledgements
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